Cyclophosphamide plus topotecan in children with recurrent or refractory solid tumors: A pediatric oncology group phase II study

Journal of Clinical Oncology

Volumn 19, Issue 15, 2001, Pages 3463-3469

  Saylors III, R L ^a   Stine, K C ^a   Sullivan, J ^a   Kepner, J L ^a   Wall, D A ^a   Bernstein, M L ^a   Harris, M B ^a   Hayashi, R ^a   Vietti, T J ^a  

^a CHILDREN S ONCOLOGY GROUP   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; TOPOTECAN;

ADOLESCENT; ADULT; ANDROBLASTOMA; ANEMIA; ARTICLE; BONE MARROW SUPPRESSION; CHILD; CHILDHOOD CANCER; CLINICAL TRIAL; DRUG INDUCED DISEASE; DRUG INFUSION; DRUG RESPONSE; EWING SARCOMA; FEMALE; HEMATURIA; HUMAN; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NAUSEA; NEUROBLASTOMA; NEUTROPENIA; OSTEOSARCOMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RECURRENT DISEASE; RHABDOMYOSARCOMA; SOLID TUMOR; THROMBOCYTOPENIA; TREATMENT OUTCOME; VOMITING;

EID: 0035424844     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2001.19.15.3463     Document Type: Article

References (19)

1. The current status of camptothecin analogues as antitumor agents
2. DNA topoisomerase poisons as antitumor drugs
3. Topoisomerase inhibitors: A review of their therapeutic potential in cancer
4. Topotecan in combination chemotherapy
5. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer
6. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: A Pediatric Oncology Group study
7. Pilot study of topotecan and high-dose cyclophosphamide for resistant pediatric solid tumors
8. Legalized peeking in tests about a binomial proportion
9. Topotecan in pediatric patients with recurrent and progressive solid tumors: A Pediatric Oncology Group phase II study
10. The drug pair, topotecan/cyclophosphamide, is active in previously untreated rhabdomyosarcoma: A report from the Intergroup Rhabdomyosarcoma Study Group
11. Systemic exposure to topotecan related to antitumor response in human neuroblastoma xenografts
12. Relationship between topotecan systemic exposure and tumor response in human neuroblastoma xenografts
13. Treatment of human cancer xenografts with camptothecin analog in combination with cytoxan or X-irradiation
14. Enhancement of irinotecan (CPT-11) activity against central nervous system tumor xenografts by alkylating agents
15. Schedule-dependent activity of irinotecan plus BCNU against malignant glioma xenografts
16. Pharmacokinetically-guided use of topotecan (TPT), given (daily × 5) × 2, in children with relapsed solid tumors
17. Phase II trial of topotecan administered as a 72-hour continuous infusion in children with refractory solid tumors: A collaborative Pediatric Branch-National Cancer Institute, and Children's Cancer Group Study
18. Continuous infusion of low-dose topotecan: Pharmacokinetics and pharmacodynamics during a phase II study in patients with small-cell lung cancer
19. Phase I study of topotecan administered as a 21 day continuous infusion in children with recurrent solid tumors: A report from the Children's Cancer Group